{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:51:00Z","timestamp":1781877060488,"version":"3.54.5"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04214-3","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:00:40Z","timestamp":1768982440000},"page":"2468-2480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress in diagnosis and treatment of pancreatic cancer with mismatch repair and microsatellite instability"],"prefix":"10.1007","volume":"28","author":[{"given":"Hang","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0539-7355","authenticated-orcid":false,"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"12","key":"4214_CR1","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1080\/0284186x.2017.1351036","volume":"56","author":"TC Weble","year":"2017","unstructured":"Weble TC, Bjerregaard JK, Kissmeyer P, Vyberg M, Hansen CP, Holl\u00e4nder NH, et al. Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943\u20132012. Acta Oncol. 2017;56(12):1763\u20138. https:\/\/doi.org\/10.1080\/0284186x.2017.1351036.","journal-title":"Acta Oncol"},{"issue":"10","key":"4214_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70960","volume":"14","author":"Z Kaplan","year":"2025","unstructured":"Kaplan Z, Prezioso E, Jain A, Lavu H, Yeo CJ, Bowne WB, et al. Clinical implications of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Cancer Med. 2025;14(10):e70960. https:\/\/doi.org\/10.1002\/cam4.70960.","journal-title":"Cancer Med"},{"issue":"1","key":"4214_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12463-8","volume":"24","author":"T Bardol","year":"2024","unstructured":"Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, et al. Early detection of pancreatic cancer by liquid biopsy \u201cPANLIPSY\u201d: a french nation-wide study project. BMC Cancer. 2024;24(1):709. https:\/\/doi.org\/10.1186\/s12885-024-12463-8.","journal-title":"BMC Cancer"},{"key":"4214_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217658","volume":"619","author":"X Li","year":"2025","unstructured":"Li X, Chen Y, Qiao G, Ni J, Chen T, Wang Y, et al. 5-year survival rate over 20 % in pancreatic ductal adenocarcinoma: a retrospective study from a Chinese high-volume center. Cancer Lett. 2025;619:217658. https:\/\/doi.org\/10.1016\/j.canlet.2025.217658.","journal-title":"Cancer Lett"},{"issue":"2","key":"4214_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386-402.e1. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","journal-title":"Gastroenterology"},{"issue":"9","key":"4214_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4(9):101162. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101162.","journal-title":"Cell Rep Med"},{"key":"4214_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245796","author":"M Sheinin","year":"2023","unstructured":"Sheinin M, Mondal S, Pahan K. Neutralization of p40 homodimer and p40 monomer leads to tumor regression in patient-derived xenograft mice with pancreatic cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15245796.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4214_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;164(5):752\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2023.02.012.","journal-title":"Gastroenterology"},{"issue":"1","key":"4214_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/eus.0000000000000109","volume":"14","author":"RM Ibrahim","year":"2025","unstructured":"Ibrahim RM, Solanki S, Qiao W, Hwang H, Singh BS, Cazacu IM, et al. Fatty pancreas on EUS: risk factors, correlation with CT\/MRI, and implications for pancreatic cancer screening. Endosc Ultrasound. 2025;14(1):13\u20139. https:\/\/doi.org\/10.1097\/eus.0000000000000109.","journal-title":"Endosc Ultrasound"},{"key":"4214_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020351","author":"V Granata","year":"2023","unstructured":"Granata V, Fusco R, Setola SV, Galdiero R, Maggialetti N, Silvestro L, et al. Risk assessment and pancreatic cancer: diagnostic management and artificial intelligence. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15020351.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4214_CR11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44382","volume":"15","author":"LSN Janga","year":"2023","unstructured":"Janga LSN, Sambe HG, Yasir M, Man RK, Gogikar A, Nanda A, et al. Holistic understanding of the role of carbohydrate antigen 19-9 in pancreatic cancer screening, early diagnosis, and prognosis: a systematic review. Cureus. 2023;15(8):e44382. https:\/\/doi.org\/10.7759\/cureus.44382.","journal-title":"Cureus"},{"issue":"2","key":"4214_CR12","first-page":"533","volume":"33","author":"SMF Ahmed","year":"2024","unstructured":"Ahmed SMF, Ullah AKM, Mohammed S, Chowdhury ASM, Haque MM, Rana AMM. Evaluation of serum CA 19\u20139 as a diagnostic marker for pancreatic malignancy. Mymensingh Med J. 2024;33(2):533\u20139.","journal-title":"Mymensingh Med J"},{"issue":"3","key":"4214_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153\u201368. https:\/\/doi.org\/10.1038\/s41575-019-0245-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4214_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","volume":"13","author":"Y Qian","year":"2020","unstructured":"Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1):130. https:\/\/doi.org\/10.1186\/s13045-020-00958-3.","journal-title":"J Hematol Oncol"},{"key":"4214_CR15","unstructured":"Tanti A (2019) Estimate of mismatch repair deficient pancreatic cancer in patients enrolled in the Quebec Pancreas Cancer Study. McGill University (Canada)."},{"key":"4214_CR16","unstructured":"Golesworthy J (2021) Characterization of the immune microenvironment of homologous recombination deficient pancreatic cancer. McGill University (Canada)."},{"key":"4214_CR17","doi-asserted-by":"crossref","unstructured":"Kamgar M, Korn WM (2019) Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. Textbook of Gastrointestinal Oncology, 2019: p. 613\u2013631.","DOI":"10.1007\/978-3-030-18890-0_34"},{"issue":"1","key":"4214_CR18","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","volume":"12","author":"YJ Kang","year":"2022","unstructured":"Kang YJ, O\u2019Haire S, Franchini F, IJzerman M, Zalcberg J, Macrae F, et al. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Sci Rep. 2022;12(1):20495. https:\/\/doi.org\/10.1038\/s41598-022-23319-1.","journal-title":"Sci Rep"},{"issue":"1","key":"4214_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00535-019-01620-7","volume":"55","author":"Y Eso","year":"2020","unstructured":"Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55(1):15\u201326. https:\/\/doi.org\/10.1007\/s00535-019-01620-7.","journal-title":"J Gastroenterol"},{"key":"4214_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204925","author":"R Walker","year":"2023","unstructured":"Walker R, Mahmood K, Como J, Clendenning M, Joo JE, Georgeson P, et al. DNA mismatch repair gene variant classification: evaluating the utility of somatic mutations and mismatch repair deficient colonic crypts and endometrial glands. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15204925.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4214_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/jmg-2022-108800","volume":"60","author":"L Loong","year":"2023","unstructured":"Loong L, Huntley C, McRonald F, Santaniello F, Pethick J, Torr B, et al. Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996-2020: development of a national resource of patient-level genomics laboratory records. J Med Genet. 2023;60(7):669\u201378. https:\/\/doi.org\/10.1136\/jmg-2022-108800.","journal-title":"J Med Genet"},{"issue":"2","key":"4214_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3724\/zdxbyxb-2022-0611","volume":"52","author":"B Fang","year":"2023","unstructured":"Fang B, Wei Y, Pan J, Zhang T, Ye D, Zhu Y. Mismatch repair gene germline mutations in patients with prostate cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52(2):133\u20138. https:\/\/doi.org\/10.3724\/zdxbyxb-2022-0611.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"4214_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2024.103791","volume":"145","author":"H Trost","year":"2025","unstructured":"Trost H, Lopezcolorado FW, Merkell A, Stark JM. Functions of PMS2 and MLH1 important for regulation of divergent repeat-mediated deletions. DNA Repair (Amst). 2025;145:103791. https:\/\/doi.org\/10.1016\/j.dnarep.2024.103791.","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"4214_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41698-024-00511-2","volume":"8","author":"M Koi","year":"2024","unstructured":"Koi M, Leach BH, McGee S, Tseng-Rogenski SS, Burke CA, Carethers JM. Compound heterozygous MSH3 germline variants and associated tumor somatic DNA mismatch repair dysfunction. NPJ Precis Oncol. 2024;8(1):12. https:\/\/doi.org\/10.1038\/s41698-024-00511-2.","journal-title":"NPJ Precis Oncol"},{"key":"4214_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2022.103405","volume":"119","author":"ML DuPrie","year":"2022","unstructured":"DuPrie ML, Palacio T, Calil FA, Kolodner RD, Putnam CD. Mlh1 interacts with both Msh2 and Msh6 for recruitment during mismatch repair. DNA Repair. 2022;119:103405. https:\/\/doi.org\/10.1016\/j.dnarep.2022.103405.","journal-title":"DNA Repair"},{"key":"4214_CR26","doi-asserted-by":"publisher","first-page":"115233","DOI":"10.1016\/j.ejca.2025.115233","volume":"217","author":"K Venetis","year":"2025","unstructured":"Venetis K, Frascarelli C, Bielo LB, Cursano G, Adorisio R, Ivanova M, et al. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact. Eur J Cancer. 2025;217:115233. https:\/\/doi.org\/10.1016\/j.ejca.2025.115233.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4214_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12022-020-09612-7","volume":"31","author":"C Fraune","year":"2020","unstructured":"Fraune C, Simon R, Hube-Magg C-M, Makrypidi-Fraune G, Kluth M, B\u00fcscheck F, et al. Homogeneous MMR deficiency throughout the entire tumor mass occurs in a subset of colorectal neuroendocrine carcinomas. Endocr Pathol. 2020;31(2):182\u20139. https:\/\/doi.org\/10.1007\/s12022-020-09612-7.","journal-title":"Endocr Pathol"},{"issue":"23","key":"4214_CR28","doi-asserted-by":"publisher","first-page":"25271","DOI":"10.18632\/aging.203745","volume":"13","author":"H Zhan","year":"2021","unstructured":"Zhan H, Mo F, Xu Q, Wang S, Zhang B, Liu X, et al. An integrative pan-cancer analysis reveals the oncogenic role of mutS homolog 6 (MSH6) in human tumors. Aging (Albany NY). 2021;13(23):25271\u201390. https:\/\/doi.org\/10.18632\/aging.203745.","journal-title":"Aging (Albany NY)"},{"key":"4214_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081878","author":"U Malapelle","year":"2021","unstructured":"Malapelle U, Parente P, Pepe F, De Luca C, Pisapia P, Sgariglia R, et al. Evaluation of micro satellite instability and mismatch repair status in different solid tumors: a multicenter analysis in a real world setting. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10081878.","journal-title":"Cells"},{"issue":"6","key":"4214_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00428-021-03205-3","volume":"480","author":"C Luchini","year":"2022","unstructured":"Luchini C, Mafficini A, Chatterjee D, Piredda ML, Sciammarella C, Navale P, et al. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Arch. 2022;480(6):1261\u20138. https:\/\/doi.org\/10.1007\/s00428-021-03205-3.","journal-title":"Virchows Arch"},{"key":"4214_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.933475","volume":"13","author":"S Han","year":"2022","unstructured":"Han S, Chok AY, Peh DYY, Ho JZ, Tan EKW, Koo SL, et al. The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers. Front Genet. 2022;13:933475. https:\/\/doi.org\/10.3389\/fgene.2022.933475.","journal-title":"Front Genet"},{"issue":"1","key":"4214_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12332-4","volume":"24","author":"J Cai","year":"2024","unstructured":"Cai J, Yang Y, Zhang L, Fang Y, Zhang Y, Tan M, et al. Investigation of ENO2 as a promising novel marker for the progression of colorectal cancer with microsatellite instability-high. BMC Cancer. 2024;24(1):573. https:\/\/doi.org\/10.1186\/s12885-024-12332-4.","journal-title":"BMC Cancer"},{"key":"4214_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007104","author":"G Randon","year":"2023","unstructured":"Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, et al. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007104.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4214_CR34","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang X, Fang Y, Liang W, Wong CC, Qin H, Gao Y, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024;42(10):1729-1746.e8. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.019.","journal-title":"Cancer Cell"},{"issue":"6","key":"4214_CR35","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/cas.16160","volume":"115","author":"H Yamamoto","year":"2024","unstructured":"Yamamoto H, Watanabe Y, Arai H, Umemoto K, Tateishi K, Sunakawa Y. Microsatellite instability: a 2024 update. Cancer Sci. 2024;115(6):1738\u201348. https:\/\/doi.org\/10.1111\/cas.16160.","journal-title":"Cancer Sci"},{"issue":"1","key":"4214_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02866-y","volume":"21","author":"T Wu","year":"2023","unstructured":"Wu T, Zhang X, Liu X, Cai X, Shen T, Pan D, et al. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability. BMC Med. 2023;21(1):161. https:\/\/doi.org\/10.1186\/s12916-023-02866-y.","journal-title":"BMC Med"},{"issue":"11","key":"4214_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03805-3","volume":"73","author":"JH Kim","year":"2024","unstructured":"Kim JH, Hong J, Lee JA, Jung M, Choi E, Cho NY, et al. Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers. Cancer Immunol Immunother. 2024;73(11):215. https:\/\/doi.org\/10.1007\/s00262-024-03805-3.","journal-title":"Cancer Immunol Immunother"},{"key":"4214_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4719194","volume":"2017","author":"G Viale","year":"2017","unstructured":"Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. Biomed Res Int. 2017;2017:4719194. https:\/\/doi.org\/10.1155\/2017\/4719194.","journal-title":"Biomed Res Int"},{"issue":"7","key":"4214_CR39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/jco.21.01874","volume":"40","author":"DM O'Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752\u201361. https:\/\/doi.org\/10.1200\/jco.21.01874.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4214_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/jco.19.02105.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4214_CR41","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jamaoncol.2024.3651","volume":"10","author":"CA O'Connor","year":"2024","unstructured":"O\u2019Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, et al. Lynch syndrome and somatic mismatch repair variants in pancreas cancer. JAMA Oncol. 2024;10(11):1511\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3651.","journal-title":"JAMA Oncol"},{"key":"4214_CR42","doi-asserted-by":"publisher","first-page":"101909","DOI":"10.1016\/j.eclinm.2023.101909","volume":"58","author":"M Dominguez-Valentin","year":"2023","unstructured":"Dominguez-Valentin M, Haupt S, Sepp\u00e4l\u00e4 TT, Sampson JR, Sunde L, Bernstein I, et al. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database. EClinicalMedicine. 2023;58:101909. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101909.","journal-title":"EClinicalMedicine"},{"key":"4214_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1147591","volume":"13","author":"M Rasmussen","year":"2023","unstructured":"Rasmussen M, Sowter P, Gallon R, Durhuus JA, Hayes C, Andersen O, et al. Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors. Front Oncol. 2023;13:1147591. https:\/\/doi.org\/10.3389\/fonc.2023.1147591.","journal-title":"Front Oncol"},{"issue":"10","key":"4214_CR44","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/jco.2016.71.0012","volume":"35","author":"MB Yurgelun","year":"2017","unstructured":"Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35(10):1086\u201395. https:\/\/doi.org\/10.1200\/jco.2016.71.0012.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4214_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/1055-9965.Epi-16-0693","volume":"26","author":"AK Win","year":"2017","unstructured":"Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(3):404\u201312. https:\/\/doi.org\/10.1158\/1055-9965.Epi-16-0693.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"4214_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3322\/caac.21448","volume":"68","author":"PM Boland","year":"2018","unstructured":"Boland PM, Yurgelun MB, Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018;68(3):217\u201331. https:\/\/doi.org\/10.3322\/caac.21448.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4214_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148(3):556\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.042.","journal-title":"Gastroenterology"},{"issue":"8","key":"4214_CR48","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156(8):2242-2253.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.037.","journal-title":"Gastroenterology"},{"issue":"6","key":"4214_CR49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40291-022-00614-1","volume":"26","author":"B Zheng-Lin","year":"2022","unstructured":"Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, et al. Methylation analyses reveal promoter hypermethylation as a rare cause of \u201csecond hit\u201d in germline BRCA1-associated pancreatic ductal adenocarcinoma. Mol Diagn Ther. 2022;26(6):645\u201353. https:\/\/doi.org\/10.1007\/s40291-022-00614-1.","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"4214_CR50","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1016\/j.cgh.2021.04.021","volume":"20","author":"EL Eikenboom","year":"2022","unstructured":"Eikenboom EL, van der Werf-\u2019t Lam AS, Rodr\u00edguez-Girondo M, Van Asperen CJ, Dinjens WNM, Hofstra RMW, et al. Universal immunohistochemistry for Lynch syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas. Clin Gastroenterol Hepatol. 2022;20(3):e496\u2013507. https:\/\/doi.org\/10.1016\/j.cgh.2021.04.021.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4214_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29920-2","volume":"13","author":"BCH Lee","year":"2022","unstructured":"Lee BCH, Robinson PS, Coorens THH, Yan HHN, Olafsson S, Lee-Six H, et al. Mutational landscape of normal epithelial cells in Lynch Syndrome patients. Nat Commun. 2022;13(1):2710. https:\/\/doi.org\/10.1038\/s41467-022-29920-2.","journal-title":"Nat Commun"},{"key":"4214_CR52","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fonc.2019.00550","volume":"9","author":"S Sun","year":"2019","unstructured":"Sun S, Liu Y, Eisfeld AK, Zhen F, Jin S, Gao W, et al. Identification of germline mismatch repair gene mutations in lung cancer patients with paired tumor-normal next generation sequencing: a retrospective study. Front Oncol. 2019;9:550. https:\/\/doi.org\/10.3389\/fonc.2019.00550.","journal-title":"Front Oncol"},{"key":"4214_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051115","author":"A Mart\u00ednez-Roca","year":"2022","unstructured":"Mart\u00ednez-Roca A, Giner-Calabuig M, Murcia O, Castillejo A, Soto JL, Garc\u00eda-Heredia A, et al. Lynch-like syndrome: potential mechanisms and management. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14051115.","journal-title":"Cancers (Basel)"},{"key":"4214_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112111","author":"M Emelyanova","year":"2024","unstructured":"Emelyanova M, Ikonnikova A, Pushkov A, Pudova E, Krasnov G, Popova A, et al. Mutations in mismatch repair genes and microsatellite instability status in pancreatic cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16112111.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4214_CR55","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.gastro.2016.09.060","volume":"152","author":"JL Humphris","year":"2017","unstructured":"Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152(1):68-74.e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.060.","journal-title":"Gastroenterology"},{"issue":"6","key":"4214_CR56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/jamaoncol.2016.3916","volume":"3","author":"AA Connor","year":"2017","unstructured":"Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 2017;3(6):774\u201383. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3916.","journal-title":"JAMA Oncol"},{"issue":"Suppl_8","key":"4214_CR57","doi-asserted-by":"publisher","first-page":"viii36","DOI":"10.1093\/annonc\/mdz385","volume":"30","author":"EM O'Reilly","year":"2019","unstructured":"O\u2019Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 2019;30(Suppl_8):viii36\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdz385.","journal-title":"Ann Oncol"},{"issue":"7","key":"4214_CR58","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","volume":"30","author":"AB Schrock","year":"2019","unstructured":"Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096\u2013103. https:\/\/doi.org\/10.1093\/annonc\/mdz134.","journal-title":"Ann Oncol"},{"key":"4214_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133119","author":"RT Lawlor","year":"2021","unstructured":"Lawlor RT, Mattiolo P, Mafficini A, Hong SM, Piredda ML, Taormina SV, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13133119.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4214_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176181","volume":"12","author":"LA Albacker","year":"2017","unstructured":"Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11):e0176181. https:\/\/doi.org\/10.1371\/journal.pone.0176181.","journal-title":"PLoS ONE"},{"issue":"7","key":"4214_CR61","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ijc.30573","volume":"140","author":"P Garc\u00eda-Sanz","year":"2017","unstructured":"Garc\u00eda-Sanz P, Trivi\u00f1o JC, Mota A, P\u00e9rez L\u00f3pez M, Col\u00e1s E, Rojo-Sebasti\u00e1n \u00c1, et al. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. Int J Cancer. 2017;140(7):1551\u201363. https:\/\/doi.org\/10.1002\/ijc.30573.","journal-title":"Int J Cancer"},{"issue":"3","key":"4214_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10689-024-00381-4","volume":"23","author":"M Goggins","year":"2024","unstructured":"Goggins M. The role of biomarkers in the early detection of pancreatic cancer. Fam Cancer. 2024;23(3):309\u201322. https:\/\/doi.org\/10.1007\/s10689-024-00381-4.","journal-title":"Fam Cancer"},{"issue":"14","key":"4214_CR63","doi-asserted-by":"publisher","first-page":"13437","DOI":"10.1007\/s00432-023-05149-4","volume":"149","author":"S Maloney","year":"2023","unstructured":"Maloney S, Clarke SJ, Sahni S, Hudson A, Colvin E, Mittal A, et al. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. J Cancer Res Clin Oncol. 2023;149(14):13437\u201350. https:\/\/doi.org\/10.1007\/s00432-023-05149-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"4214_CR64","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48721","volume":"5","author":"L Yin","year":"2022","unstructured":"Yin L, Wei J, Lu Z, Huang S, Gao H, Chen J, et al. Prevalence of germline sequence variations among patients with pancreatic cancer in China. JAMA Netw Open. 2022;5(2):e2148721. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48721.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"4214_CR65","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.Ccr-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24(6):1326\u201336. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3099.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4214_CR66","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/gutjnl-2021-326033","volume":"71","author":"V Kryklyva","year":"2022","unstructured":"Kryklyva V, Luchini C, Stommel MWJ, Nagtegaal ID, Brosens LAA. Detecting Lynch syndrome in pancreatic ductal adenocarcinoma FNA cytology based on cancer history and immunocytochemistry. Gut. 2022;71(7):1450\u20131. https:\/\/doi.org\/10.1136\/gutjnl-2021-326033.","journal-title":"Gut"},{"issue":"1","key":"4214_CR67","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini C, Brosens LAA, Wood LD, Chatterjee D, Shin JI, Sciammarella C, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148\u201356. https:\/\/doi.org\/10.1136\/gutjnl-2020-320726.","journal-title":"Gut"},{"issue":"12","key":"4214_CR68","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.Ccr-21-3581","volume":"28","author":"PA Philip","year":"2022","unstructured":"Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022;28(12):2704\u201314. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3581.","journal-title":"Clin Cancer Res"},{"key":"4214_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184446","author":"M Valery","year":"2023","unstructured":"Valery M, Vasseur D, Fachinetti F, Boil\u00e8ve A, Smolenschi C, Tarabay A, et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15184446.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4214_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.152985","volume":"216","author":"SA Ahmad-Nielsen","year":"2020","unstructured":"Ahmad-Nielsen SA, Bruun Nielsen MF, Mortensen MB, Detlefsen S. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Pathol Res Pract. 2020;216(6):152985. https:\/\/doi.org\/10.1016\/j.prp.2020.152985.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"4214_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100120","volume":"6","author":"A Guyot D'Asnieres De Salins","year":"2021","unstructured":"Guyot D\u2019Asnieres De Salins A, Tachon G, Cohen R, Karayan-Tapon L, Junca A, Frouin E, et al. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. ESMO Open. 2021;6(3):100120. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100120.","journal-title":"ESMO Open"},{"issue":"4","key":"4214_CR72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439\u201357. https:\/\/doi.org\/10.6004\/jnccn.2021.0017.","journal-title":"J Natl Compr Canc Netw"},{"key":"4214_CR73","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/B978-0-443-13376-3.00014-9","volume-title":"Principles of Immunotherapy Breast and Gastrointestinal Cancers","author":"M Salati","year":"2025","unstructured":"Salati M, Rizzo A, Ricci AD, Petrillo A, Parisi A. Immunotherapeutic strategies in hepatopancreatobiliary cancers. In: Principles of Immunotherapy Breast and Gastrointestinal Cancers. Elsevier; 2025. p. 103\u201324."},{"key":"4214_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/tgh.2019.01.12","volume":"4","author":"O Gbolahan","year":"2019","unstructured":"Gbolahan O, O\u2019Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol. 2019;4:9. https:\/\/doi.org\/10.21037\/tgh.2019.01.12.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"3","key":"4214_CR75","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00262-024-03926-9","volume":"74","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Liu Y, Huang H, Zhao T, Zhao Z, Gao Y. Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H\/dMMR colorectal cancer. Cancer Immunol Immunother. 2025;74(3):78. https:\/\/doi.org\/10.1007\/s00262-024-03926-9.","journal-title":"Cancer Immunol Immunother"},{"key":"4214_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004485","author":"S Chakrabarti","year":"2022","unstructured":"Chakrabarti S, Bucheit L, Starr JS, Innis-Shelton R, Shergill A, Dada H, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004485.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4214_CR77","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2217\/imt-2022-0012","volume":"14","author":"DS Lefler","year":"2022","unstructured":"Lefler DS, Snook AE, Bashir B. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H\/dMMR, TMB\u00a0and PD-L1. Immunotherapy. 2022;14(11):885\u2013902. https:\/\/doi.org\/10.2217\/imt-2022-0012.","journal-title":"Immunotherapy"},{"issue":"6","key":"4214_CR78","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.18632\/oncotarget.14069","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, Lin J, Cui J, Han T, Jiao F, Meng Z, et al. Prognostic value and clinicopathological features of PD-1\/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. Oncotarget. 2017;8(6):9354\u201365. https:\/\/doi.org\/10.18632\/oncotarget.14069.","journal-title":"Oncotarget"},{"issue":"5","key":"4214_CR79","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1245\/s10434-024-16621-x","volume":"32","author":"EL Eikenboom","year":"2025","unstructured":"Eikenboom EL, Nasar N, Seier K, G\u00f6nen M, Spaander MCW, O\u2019Reilly EM, et al. Survival of patients with resected microsatellite instability-high, mismatch repair deficient, and Lynch syndrome-associated pancreatic ductal adenocarcinomas. Ann Surg Oncol. 2025;32(5):3568\u201377. https:\/\/doi.org\/10.1245\/s10434-024-16621-x.","journal-title":"Ann Surg Oncol"},{"key":"4214_CR80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.humpath.2022.12.016","volume":"135","author":"H Matsubayashi","year":"2023","unstructured":"Matsubayashi H, Oishi T, Sasaki K, Abe M, Kiyozumi Y, Higashigawa S, et al. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type. Hum Pathol. 2023;135:54\u201364. https:\/\/doi.org\/10.1016\/j.humpath.2022.12.016.","journal-title":"Hum Pathol"},{"key":"4214_CR81","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00706","volume":"7","author":"T Coston","year":"2023","unstructured":"Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: Mayo Clinic experience. JCO Precis Oncol. 2023;7:e2200706. https:\/\/doi.org\/10.1200\/po.22.00706.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4214_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-025-01237-5","volume":"56","author":"V Muralidharan","year":"2025","unstructured":"Muralidharan V, Brown S, Upton A, Alshimirti M, Cooray PD. Neoadjuvant pembrolizumab enables successful downstaging and resection of borderline resectable MSI-H\/dMMR pancreatic ductal adenocarcinoma: a case report and literature review. J Gastrointest Cancer. 2025;56(1):112. https:\/\/doi.org\/10.1007\/s12029-025-01237-5.","journal-title":"J Gastrointest Cancer"},{"issue":"22","key":"4214_CR83","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00018-018-2906-9","volume":"75","author":"M Ratti","year":"2018","unstructured":"Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75(22):4151\u201362. https:\/\/doi.org\/10.1007\/s00018-018-2906-9.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"4214_CR84","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cam4.1372","volume":"7","author":"A Vanderwalde","year":"2018","unstructured":"Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746\u201356. https:\/\/doi.org\/10.1002\/cam4.1372.","journal-title":"Cancer Med"},{"issue":"4","key":"4214_CR85","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2023.05.036","volume":"165","author":"S Yousuf","year":"2023","unstructured":"Yousuf S, Qiu M, von Voith Voithenberg L, Hulkkonen J, Macinkovic I, Schulz AR, et al. Spatially resolved multi-omics single-cell analyses inform mechanisms of immune dysfunction in pancreatic cancer. Gastroenterology. 2023;165(4):891-908.e14. https:\/\/doi.org\/10.1053\/j.gastro.2023.05.036.","journal-title":"Gastroenterology"},{"issue":"1","key":"4214_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat Commun. 2023;14(1):797. https:\/\/doi.org\/10.1038\/s41467-023-36296-4.","journal-title":"Nat Commun"},{"key":"4214_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104430","volume":"203","author":"Y Li","year":"2024","unstructured":"Li Y, Du Y, Li R, Zhong W, Zou X, Li L, et al. Spatial transcriptomics in pancreatic cancer: advances, prospects and challenges. Crit Rev Oncol Hematol. 2024;203:104430. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104430.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4214_CR88","doi-asserted-by":"publisher","first-page":"22218","DOI":"10.1038\/s41598-023-49752-4","volume":"13","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, Kong X, Mei H, Wang J, Zhou S. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer. Sci Rep. 2023;13(1):22218. https:\/\/doi.org\/10.1038\/s41598-023-49752-4.","journal-title":"Sci Rep"},{"key":"4214_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154726","volume":"249","author":"S Jafari","year":"2023","unstructured":"Jafari S, Ravan M, Karimi-Sani I, Aria H, Hasan-Abad AM, Banasaz B, et al. Screening and identification of potential biomarkers for pancreatic cancer: an integrated bioinformatics analysis. Pathol Res Pract. 2023;249:154726. https:\/\/doi.org\/10.1016\/j.prp.2023.154726.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"4214_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79619-1","volume":"14","author":"Y Li","year":"2024","unstructured":"Li Y, Pan L, Mugaanyi J, Li H, Li G, Huang J, et al. Pathomic and bioinformatics analysis of clinical-pathological and genomic factors for pancreatic cancer prognosis. Sci Rep. 2024;14(1):27769. https:\/\/doi.org\/10.1038\/s41598-024-79619-1.","journal-title":"Sci Rep"},{"issue":"7963","key":"4214_CR91","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"issue":"5","key":"4214_CR92","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/j.gastro.2024.05.032","volume":"167","author":"A Boil\u00e8ve","year":"2024","unstructured":"Boil\u00e8ve A, Cartry J, Goudarzi N, Bedja S, Mathieu JRR, Bani MA, et al. Organoids for functional precision medicine in advanced pancreatic cancer. Gastroenterology. 2024;167(5):961-976.e13. https:\/\/doi.org\/10.1053\/j.gastro.2024.05.032.","journal-title":"Gastroenterology"},{"issue":"6","key":"4214_CR93","doi-asserted-by":"publisher","first-page":"959","DOI":"10.23736\/s0026-4806.21.07669-2","volume":"113","author":"MR Alam","year":"2022","unstructured":"Alam MR, Kim YH, Alhazmi A, Haque S, Kang YN, Jung HR, et al. Analysis of microsatellite instability in Korean patients with pancreatic cancer. Minerva Med. 2022;113(6):959\u201366. https:\/\/doi.org\/10.23736\/s0026-4806.21.07669-2.","journal-title":"Minerva Med"},{"key":"4214_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030897","author":"LK Stuhr","year":"2023","unstructured":"Stuhr LK, Madsen K, Johansen AZ, Chen IM, Hansen CP, Jensen LH, et al. Combining sCD163 with CA 19-9 increases the predictiveness of pancreatic ductal adenocarcinoma. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030897.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4214_CR95","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.pan.2022.06.260","volume":"22","author":"IJ Visser","year":"2022","unstructured":"Visser IJ, Levink IJM, Peppelenbosch MP, Fuhler GM, Bruno MJ, Cahen DL. Systematic review and meta-analysis: diagnostic performance of DNA alterations in pancreatic juice for the detection of pancreatic cancer. Pancreatology. 2022;22(7):973\u201386. https:\/\/doi.org\/10.1016\/j.pan.2022.06.260.","journal-title":"Pancreatology"},{"issue":"4","key":"4214_CR96","doi-asserted-by":"publisher","first-page":"401","DOI":"10.30476\/ijms.2022.95583.2705","volume":"48","author":"Y Gong","year":"2023","unstructured":"Gong Y, Song L, Ou L, Lu YY, Huang X, Zeng Q. Diagnostic and prognostic performance of MicroRNA-25, carbohydrate antigen 19\u20139, carcinoembryonic antigen, and carbohydrate antigen 125 in pancreatic ductal adenocarcinoma. Iran J Med Sci. 2023;48(4):401\u201313. https:\/\/doi.org\/10.30476\/ijms.2022.95583.2705.","journal-title":"Iran J Med Sci"},{"issue":"1","key":"4214_CR97","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12957-025-03818-x","volume":"23","author":"Z Li","year":"2025","unstructured":"Li Z, Ren H, Zhang S, Sun C, Li Z, Niu P, et al. PD-L1 levels, TP53 mutation profiles, and survival outcomes in pancreatic cancer differ by immune-nutritional status. World J Surg Oncol. 2025;23(1):174. https:\/\/doi.org\/10.1186\/s12957-025-03818-x.","journal-title":"World J Surg Oncol"},{"key":"4214_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051989","author":"S Maloney","year":"2023","unstructured":"Maloney S, Pavlakis N, Itchins M, Arena J, Mittal A, Hudson A, et al. The prognostic and predictive role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as biomarkers in resected pancreatic cancer. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12051989.","journal-title":"J Clin Med"},{"issue":"1","key":"4214_CR99","doi-asserted-by":"publisher","first-page":"70","DOI":"10.33160\/yam.2020.02.011","volume":"63","author":"M Morimoto","year":"2020","unstructured":"Morimoto M, Honjo S, Sakamoto T, Yagyu T, Uchinaka E, Hanaki T, et al. Prognostic impact of pre- and post-operative P-CRP levels in pancreatic cancer patients. Yonago Acta Med. 2020;63(1):70\u20138. https:\/\/doi.org\/10.33160\/yam.2020.02.011.","journal-title":"Yonago Acta Med"},{"issue":"3","key":"4214_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100459","volume":"7","author":"A Russo","year":"2022","unstructured":"Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, et al. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open. 2022;7(3):100459. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100459.","journal-title":"ESMO Open"},{"key":"4214_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.964115","volume":"12","author":"F Shen","year":"2022","unstructured":"Shen F, Liu C, Zhang W, He S, Wang F, Wang J, et al. Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer. Front Oncol. 2022;12:964115. https:\/\/doi.org\/10.3389\/fonc.2022.964115.","journal-title":"Front Oncol"},{"issue":"15","key":"4214_CR102","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1158\/1078-0432.Ccr-23-0887","volume":"29","author":"S Perera","year":"2023","unstructured":"Perera S, Jang GH, Grant R, Notta F, Grunwald B, Gallinger S, et al. hENT1 as a predictive biomarker in PDAC-response. Clin Cancer Res. 2023;29(15):2945\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0887.","journal-title":"Clin Cancer Res"},{"key":"4214_CR103","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.trsl.2024.08.002","volume":"273","author":"MF Lansbergen","year":"2024","unstructured":"Lansbergen MF, Dings MPG, Manoukian P, Fari\u00f1a A, Waasdorp C, Hooijer GKJ, et al. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Transl Res. 2024;273:137\u201347. https:\/\/doi.org\/10.1016\/j.trsl.2024.08.002.","journal-title":"Transl Res"},{"issue":"3","key":"4214_CR104","first-page":"1083","volume":"36","author":"S Morinaga","year":"2016","unstructured":"Morinaga S, Nakamura Y, Atsumi Y, Murakawa M, Yamaoku K, Aoyama T, et al. Locked nucleic acid in situ hybridization analysis of MicroRNA-21 predicts clinical outcome in patients after resection for pancreatic cancer treated with adjuvant gemcitabine monotherapy. Anticancer Res. 2016;36(3):1083\u20138.","journal-title":"Anticancer Res"},{"issue":"8","key":"4214_CR105","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/mpa.0000000000001888","volume":"50","author":"H Kimura","year":"2021","unstructured":"Kimura H, Klein AP, Hruban RH, Roberts NJ. The role of inherited pathogenic CDKN2A variants in susceptibility to pancreatic cancer. Pancreas. 2021;50(8):1123\u201330. https:\/\/doi.org\/10.1097\/mpa.0000000000001888.","journal-title":"Pancreas"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04214-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:21Z","timestamp":1781873841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04214-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":105,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4214"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04214-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}